Hydrophobicity‐Adaptive Polymers Trigger Fission of Tumor‐Cell‐Derived Microparticles for Enhanced Anticancer Drug Delivery

Abstract

Tumor‐cell‐derived microparticles (MPs) can function as anticancer drug‐delivery carriers. However, short blood circulation time, large‐size‐induced insufficient tumor accumulation and penetration into tumor parenchyma, as well as limited cellular internalization by tumor cells and cancer stem cells (CSCs), and difficult intracellular drug release restrict the anticancer activity of tumor‐cell‐derived MP‐based drug‐delivery systems. In this work, hydrophobicity‐adaptive polymers based on poly(N‐isopropylacrylamide) are anchored to tumor‐cell‐derived MPs for enhanced delivery of the anticancer drug doxorubicin (DOX). The polymers are hydrophilic in blood to prolong the circulation time of DOX‐loaded MPs (DOX@MPs), while rapidly switching to hydrophobic at the tumor acidic microenvironment. The hydrophobicity of polymers drives the fission of tumor‐cell‐derived MPs to form small vesicles, facilitating tumor accumulation, deep tumor penetration, and efficient internalization of DOX@MPs into tumor cells and CSCs. Subsequently, the hydrophobicity of polymers in acidic lysosomes further promotes DOX release to nuclei for strong cytotoxicity against tumor cells and CSCs. The work provides a facile and simple strategy for improved anticancer drug delivery of tumor‐cell‐derived MPs.

Tumor-derived microvesicles for cancer therapy

“…TMVs hold great potential as a drug carrier with their features of innate targeting ability, biocompatibility and low immunogenicity. 93 In this section, TMVs-mediated chemotherapy drug delivery will be discussed. In particular, current clinical applications of TMVs will be highlighted.…”